

# bDMARDs retention rate in the biosimilar era: A real-life monocentric study

Andrea Becciolini<sup>1</sup> , Federica Lumetti<sup>1,2</sup> , Eleonora Di Donato<sup>1</sup> , Salvatore Giordano<sup>1</sup> , Daniele Santilli<sup>1</sup> , Flavio Mozzani<sup>1</sup> , Michele Riva<sup>1</sup> , Gianluca Lucchini<sup>1</sup> , Alarico Ariani<sup>1</sup> 

The introduction of biological disease-modifying antirheumatic drugs (bDMARDs) in the last two decades has deeply changed the management of inflammatory arthritides. In the last 5 years, as the originator bDMARDs patents expired, less-expensive biosimilars were introduced in the market (1). The EMA and FDA defined the biosimilar as a biological agent that contains a similar version of the active substance of an already approved original biological agent (reference product). To date infliximab, etanercept, adalimumab, and rituximab biosimilars have been approved in rheumatology. The growing evidence concealing the use of biosimilar drugs in rheumatological diseases has been recently analyzed in an international consensus (2). Nevertheless, implementation of biosimilars into real world practice is still a matter of controversy among rheumatologists (3).

To evaluate the real world impact of biosimilar use in rheumatologic diseases, we retrospectively analyzed the baseline characteristics and the 18-month retention rate in a cohort of patients who received at least a course of bDMARDs in our Rheumatology Unit from January 2000 to December 2019. Patients switching from originator to biosimilar were excluded from the analysis. We stratified the study population according to biosimilar use. Descriptive data are presented by medians (interquartile range [IQR]) for continuous data or as numbers (percentages) for categorical data. Drug survival distribution curves were computed by the Kaplan-Meier method and compared by a stratified log-rank test. A Cox proportional hazards regres-

**ORCID iDs of the authors:**  
 A.B. 0000-0002-1051-8511;  
 F.L. 0000-0003-4671-7982;  
 E.D.D. 0000-0002-5466-3446;  
 S.G. 0000-0003-2191-0022;  
 D.S. 0000-0001-6640-7821;  
 F.M. 0000-0002-4738-9346;  
 M.R. 0000-0002-7666-1521;  
 G.L. 0000-0002-8685-1011;  
 A.A. 0000-0003-1428-6102.

**Cite this article as:** Becciolini A, Lumetti F, Di Donato E, Giordano S, Santilli D, Mozzani F, et al. bDMARDs retention rate in the biosimilar era: a real-life monocentric study. Eur J Rheumatol 2021; 8(2): 109-10.

<sup>1</sup> Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy


<sup>2</sup> Unit of Rheumatology, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy

**Address for Correspondence:**  
 Andrea Becciolini, Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

E-mail: beccio@yahoo.it  
 Submitted: May 09, 2020  
 Accepted: June 22, 2020  
 Available Online Date: September 3, 2020

Copyright©Author(s) - Available online at www.eurjrheumatol.org.

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Patients at risk				
	0	6	12	18
<b>boDMARDs</b>	771	663	561	497
<b>bsDMARDs</b>	149	80	39	18

**Figure 1.** 18-month drug survival of originator bDMARDs (boDMARDs) and biosimilar bDMARDs (bsDMARDs) treatment.

sion analysis stratified by indication, drug, age, disease duration, sex, treatment line, biosimilar use, and prescription year was performed. Statistical analyses were performed using MedCalc statistical software, version 18.2.1 (MedCalc Software bvba, Ostend, Belgium). P values  $\leq 0.05$  were considered statistically significant.

The analysis included 920 patients, 580 (63%) female, median age (IQR) 54 (44-64) years, median disease duration (IQR) 71 (24-167.5) months, affected by rheumatoid arthritis (477, 51.8%), psoriatic arthritis (239, 26%), and axial spondyloarthritis (204, 22.2%). The patients were treated with TNFi (infliximab, n=160 [17.4%]; etanercept, n=334 [36.3%]; adalimumab, n=394 [42.8%]) or rituximab (n=32 [3.5%]). Hundred and forty nine (16.2%) patients were treated with a biosimilar drug (infliximab, n=49 [32.9%]; etanercept, n=64 [43%]; adalimumab, n=34 [22.8%]; and rituximab, n=2 [1.3%]). The overall 18-month retention rate was 70.1%. The estimated proportions of patients maintaining originators and biosimilars were 79.3 and 58.5%, respectively, after 12 months, and 72.8 and 42.8% after 18 months (Figure 1). Originators showed a higher survival on treatment (Hazard ratio [HR] 0.43, 95% confidence intervals [CI] 0.28 to 0.67,  $p < 0.0001$ ). However, the Cox proportional hazard regression analysis stratified by indication, drug, age, disease duration, sex, treatment line, biosimilar

use, and prescription year, highlighted that the predictors significantly associated with an overall higher risk of treatment discontinuation were the year of prescription (HR 1.12, 95% CI 1.09 to 1.54;  $p < 0.0001$ ) and female sex (HR 1.42, 95% CI 1.09 to 1.85). No other significant associations were found.

In conclusion, our preliminary real-life clinical data reported a 70.1% 18-month retention rate of bDMARDs among all rheumatologic indications. Originators showed an overall higher retention rate (72.8% vs 42.8%). However, similarly to previous observations (4, 5), the only predictors of treatment discontinuation were the year of treatment prescription and female sex. Although limited by its retrospective design and by its relatively short follow-up, our study confirms that biosimilar integration into clinical practice is effective and safe.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - A.A., A.B.; Design - A.A., A.B.; Data Collection and/ or Processing - A.A., A.B., S.G., F.L., E.D.D., D.S., F.M., M.R., G.L.; Analysis and/ or Interpretation - A.A., A.B., S.G., F.L., E.D.D., D.S., F.M., M.R., G.L.; Writing Manuscript - A.A., A.B.; Critical Review - A.A., A.B., S.G., F.L., E.D.D., D.S., F.M., G.L.

**Conflict of Interest:** A.B. served as a speaker for Sano-fi-Genzyme, UCB, AbbVie and Amgen, outside the

submitted work. The other authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

1. Smolen JS, Goncalves J, Quinn M, Benedetti F, Yongkwon JY. Era of biosimilars in rheumatology: Reshaping the healthcare environment. *RMD Open* 2019; 5: e000900. [\[Crossref\]](#)
2. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. *Ann Rheum Dis* 2018; 77: 165-74. [\[Crossref\]](#)
3. Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. *Rheumatol Int* 2016; 36: 613-25. [\[Crossref\]](#)
4. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. *Ann Rheum Dis* 2015; 74: 354-60. [\[Crossref\]](#)
5. Mok CC, Chan KY, Lee KL, Tam LS, Lee KW, Hong Kong Society of Rheumatology. Factors associated with withdrawal of the anti-TNF $\alpha$  biologics in the treatment of rheumatic diseases: Data from the Hong Kong Biologics Registry. *Int J Rheum Dis* 2014; 17 Suppl 3: 1-8. [\[Crossref\]](#)